Tempus AI stock price surged to a record high on Wednesday after the healthcare-focused artificial intelligence company announced a major breakthrough from the Food and Drug Administration (FDA). It j... ...

Tempus AI (TEM) shares soared 13.6% in the last trading session to close at $88.78. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 12.3% gain over the past four weeks.Tempus AI recorded a strong price rise on investors’ optimism following the Food and Drug Administration (FDA) approval for its updated Tempus Pixel, an AI-powered cardiac imaging platform. The update allows the generation of T1 and T2 inline maps, further enhancin ...

We recently published 10 Stocks Investors Are Gobbling Up. Tempus AI, Inc. (NASDAQ:TEM) is one of the best performers on Thursday. Shares of Tempus AI surged to a seven-month high on Thursday, jumping 13.59 percent to close at $88.78 apiece as investors cheered the Food and Drug Administration’s (FDA) green light for the updated version of Tempus Pixel, its AI-powered cardiac imaging platform. During the session, the stock touched a high of $91.06, or just 39 cents shy of its 52-week high of $91.45. Tem ...

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. I am not a registered investment, tax, or legal advisor or broker and therefore cannot promise or guar ...

Key Points The company was given a green light by an important regulator. Its updated heart imaging platform received clearance for commercialization. 10 stocks we like better than Tempus AI › The stock of healthcare-focused artificial intelligence company Tempus AI (NASDAQ: TEM) was the cure for aching portfolios on Thursday. The company's share price ballooned by almost 14% on the back of a top regulator's decision about one of its products. That price pop was much more muscular than the S&P 500 ...

Tempus AI Inc. (NASDAQ:TEM) is one of the worst AI stocks to invest in according to financial media. On September 4, Northwestern Medicine and Tempus AI announced an expanded collaboration, making Northwestern Medicine the first health system to integrate David, Tempus’ generative AI-enabled clinical assistant, into its electronic health record/EHR platform. The partnership will use data and AI to advance patient care to mark a new chapter in a collaboration that began a decade ago. The integration of Dav ...

On Thursday, Tempus AI, Inc. TEM received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its updated Tempus Pixel, an AI-powered cardiac imaging platform.The update allows the generation of T1 and T2 inline maps, further enhancing the device’s cardiac MR image analysis capabilities.Tempus Pixel provides advanced viewing and automated reporting of cardiac MR images, improving efficiency and accuracy in flow visualization, functional analysis, and tissue characterization.Also Read: Temp ...

BREAKING: Core CPI Steady, Jobless Claims Highest Since Oct. 2021Tempus AI (TEM) stock jumped into a profit-taking zone Thursday after the Food and Drug Administration cleared its updated cardiac-imaging platform, Tempus Pixel.The platform uses artificial intelligence to view cardiac magnetic resonance images, or MRI. Unlike conventional MR images that only show brightness differences, Tempus Pixel's maps provide precise numerical values to cardiac tissue characteristics. This helps clinicians detect condit ...

周四，Tempus AI(TEM.US)大涨超13%，逼近此前新高，报88.81美元。消息面上，Tempus AI宣布，其 更新版的Tempus Pixel设备获得美国食品和药物管理局(FDA)的特别510(k)许可。这是一个重要的监管里 程碑，标志着该设备在心脏成像领域的升级版正式获准在美国商业使用。 ...

智通财经APP获悉，周四，Tempus AI(TEM.US)大涨超13%，逼近此前新高，报88.81美元。消息面上， Tempus AI宣布，其更新版的Tempus Pixel设备获得美国食品和药物管理局(FDA)的特别510(k)许可。这 是一个重要的监管里程碑，标志着该设备在心脏成像领域的升级版正式获准在美国商业使用。 ...